Previous close | 2.4000 |
Open | 2.4000 |
Bid | 2.4500 |
Ask | 2.7000 |
Strike | 3.50 |
Expiry date | 2025-01-17 |
Day's range | 2.4000 - 2.4000 |
Contract range | N/A |
Volume | |
Open interest | 51 |
Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Key Insights Ginkgo Bioworks Holdings' Annual General Meeting to take place on 13th of June Salary of US$250.0k is part...
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May.